Computerized Assessment of Psychosis Risk-Journal of Psychiatry and Brain Science-CSCIED科技核心评价数据库-手机版

Computerized Assessment of Psychosis Risk

Computerized Assessment of Psychosis Risk

ES评分 0 浏览量：725 下载量：0

DOI	10.20900/jpbs.20210011
刊名	Journal of Psychiatry and Brain Science JPBS
年，卷(期)	2021, 6(3)
作者	Vijay A. Mittal*,Lauren M. Ellman,Gregory P. Strauss,Elaine F. Walker,Philip R. Corlett,Jason Schiffman,Scott W. Woods,Albert R. Powers,Steven M. Silverstein,James A. Waltz,Richard Zinbarg,Shuo Chen,Trevor Williams,Joshua Kenney,James M. Gold,
作者单位	Institutes for Policy Research (IPR) and Innovations in Developmental Sciences ; Department of Psychology, Temple University, Philadelphia, PA 19122, USA ; Departments of Psychology and Neuroscience, University of Georgia, Athens, GA 30602, USA ; Department of Psychology and Program in Neuroscience, Emory University, Atlanta, GA 30322, USA ; Department of Psychiatry, Yale University, New Haven, CT 06519, USA ; Department of Psychological Science, 4201 Social and Behavioral Sciences Gateway, University of California, Irvine, CA 92697, USA ; Center for Visual Science, Departments of Psychiatry, Neuroscience and Ophthalmology, University of Rochester Medical Center, Rochester, NY 14642, USA ; Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21228, USA ; Department of Psychology, Northwestern University, Evanston, IL 60208, USA ;
Abstract	Early detection and intervention with young people at clinical high risk (CHR) for psychosis is critical for prevention efforts focused on altering the trajectory of psychosis. Early CHR research largely focused on validating clinical interviews for detecting at-risk individuals; however, this approach has limitations related to: (1) specificity (i.e., only 20% of CHR individuals convert to psychosis) and (2) the expertise and training needed to administer these interviews is limited. The purpose of our study is to develop the computerized assessment of psychosis risk (CAPR) battery, consisting of behavioral tasks that require minimal training to administer, can be administered online, and are tied to the neurobiological systems and computational mechanisms implicated in psychosis. The aims of our study are as follows: (1A) to develop a psychosis-risk calculator through the application of machine learning (ML) methods to the measures from the CAPR battery, (1B) evaluate group differences on the risk calculator score and test the hypothesis that the risk calculator score of the CHR group will differ from help-seeking and healthy controls, (1C) evaluate how baseline CAPR battery performance relates to symptomatic outcome two years later (i.e., conversion and symptomatic worsening). These aims will be explored in 500 CHR participants, 500 help-seeking individuals, and 500 healthy controls across the study sites. This project will provide a next-generation CHR battery, tied to illness mechanisms and powered by cutting-edge computational methods that can be used to facilitate the earliest possible detection of psychosis risk.
KeyWord	clinical high-risk; psychosis; schizophrenia; prodrome; risk screening; behavioral tasks; computational psychiatry; precision medicine; computerized assessment; risk calculator
基金项目
页码	-

参考文献
相关文献

1.Brown S. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry. 1997;171(6):502-8.

2.Olfson M, Gerhard T, Huang C, Crystal S, Stroup TS. Premature Mortality Among Adults With Schizophrenia in the United States. JAMA Psychiatry. 2015 Dec 1;72(12):1172.

3.Ho B-C, Nopoulos P, Flaum M, Arndt S, Andreasen NC. Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am J Psychiatry. 1998;155(9):1196-201.

4.Penttilä M, Jääskeläinen E, Hirvonen N, Isohanni M, Miettunen J. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2014;205(2):88-94.

5.Ran M-S, Xiao Y, Chui CH, Hu X-Z, Yu Y-H, Peng M-M, et al. Duration of untreated psychosis (DUP) and outcome of people with schizophrenia in rural China: 14-year follow-up study. Psychiatry Res. 2018;267:340-5.

6.Cechnicki A, Lukasz C, Kalisz A, Blądziński P, Adamczyk P, Franczyk-Glita J. Duration of untreated psychosis (DUP) and the course of schizophrenia in a 20-year follow-up study. Psychiatry Res. 2014;219(3):420-5.

7.Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry. 2008;65(1):28-37.

8.Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Ventura J, McFarlane W, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29(4):703.

9.Broome MR, Woolley JB, Johns LC, Valmaggia LR, Tabraham P, Gafoor R, et al. Outreach and support in south London (OASIS): implementation of a clinical service for prodromal psychosis and the at risk mental state. Eur Psychiatry. 2005;20(5-6):372-8.

10.Miller TJ, McGlashan TH, Rosen JL, Somjee L, Markovich PJ, Stein K, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry. 2002;159(5):863-5.

11.Phillips LJ, Yung AR, McGorry PD. Identification of young people at risk of psychosis: validation of Personal Assessment and Crisis Evaluation Clinic intake criteria. Aust N Z J Psychiatry. 2000;34:S164-9.

12.Ruhrmann S, Schultze-Lutter F, Salokangas RK, Heinimaa M, Linszen D, Dingemans P, et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry. 2010;67(3):241-51.

13.Woods SW, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen R, et al. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull. 2009;35(5):894-908.

14.Yung AR, McGorry PD. The initial prodrome in psychosis: descriptive and qualitative aspects. Aust N Z J Psychiatry. 1996;30(5):587-99.

15.Zhang T, Li H, Woodberry KA, Seidman LJ, Zheng L, Li H, et al. Prodromal psychosis detection in a counseling center population in China: an epidemiological and clinical study. Schizophr Res. 2014;152(2-3):391-9.

16.Cannon TD, Chung Y, He G, Sun D, Jacobson A, van Erp TG, et al. Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk. Biol Psychiatry. 2015;77(2):147-57.

17.Cannon TD, Yu C, Addington J, Bearden CE, Cadenhead KS, Cornblatt BA, et al. An individualized risk calculator for research in prodromal psychosis. Am J Psychiatry. 2016;173(10):980-8.

18.Carrión RE, Cornblatt BA, Burton CZ, Tso IF, Auther AM, Adelsheim S, et al. Personalized Prediction of Psychosis: External Validation of the NAPLS-2 Psychosis Risk Calculator With the EDIPPP Project. Am J Psychiatry. 2016 Jul 1;173(10):989-96.

19.de la Fuente-Sandoval C, León-Ortiz P, Favila R, Stephano S, Mamo D, Ramírez-Bermúdez J, et al. Higher Levels of Glutamate in the Associative-Striatum of Subjects with Prodromal Symptoms of Schizophrenia and Patients with First-Episode Psychosis. Neuropsychopharmacology. 2011 Aug;36(9):1781-91.

20.Dean DJ, Walther S, Bernard JA, Mittal VA. Motor Clusters Reveal Differences in Risk for Psychosis, Cognitive Functioning, and Thalamocortical Connectivity: Evidence for Vulnerability Subtypes. Clin Psychol Sci. 2018 Sep 1;6(5):721-34.

21.Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L, et al. Predicting Psychosis: Meta-analysis of Transition Outcomes in Individuals at High Clinical Risk. Arch Gen Psychiatry. 2012 Mar 1;69(3):220-9.

22.Fusar-Poli P, McGuire P, Borgwardt S. Mapping prodromal psychosis: A critical review of neuroimaging studies. Eur Psychiatry. 2012 Apr;27(3):181-91.

23.Howes OD, Montgomery AJ, Asselin M-C, Murray RM, Grasby PM, Mcguire PK. Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br J Psychiatry. 2007 Dec;191(S51):s13-8.

24.Insel TR. Rethinking schizophrenia. Nature. 2010 Nov;468(7321):187-93.

25.McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, et al. Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis. Am J Psychiatry. 2006 May 1;163(5):790-9.

26.Morrison AP, Bentall RP, French P, Walford L, Kilcommons A, Knight A, et al. Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high-risk individuals: Study design and interim analysis of transition rate and psychological risk factors. Br J Psychiatry. 2002 Sep;181(S43):s78-84.

27.Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, Cannon TD, et al. Neuropsychology of the Prodrome to Psychosis in the NAPLS Consortium: Relationship to Family History and Conversion to Psychosis. Arch Gen Psychiatry. 2010 Jun 1;67(6):578-88.

28.Walker EF, Trotman HD, Pearce BD, Addington J, Cadenhead KS, Cornblatt BA, et al. Cortisol Levels and Risk for Psychosis: Initial Findings from the North American Prodrome Longitudinal Study. Biol Psychiatry. 2013 Sep 15;74(6):410-7.

29.Hartmann JA, Yuen HP, McGorry PD, Yung AR, Lin A, Wood SJ, et al. Declining transition rates to psychotic disorder in “ultra-high risk” clients: Investigation of a dilution effect. Schizophr Res. 2016 Jan 1;170(1):130-6.

30.Nelson B, Yuen HP, Wood SJ, Lin A, Spiliotacopoulos D, Bruxner A, et al. Long-term Follow-up of a Group at Ultra High Risk (“Prodromal”) for Psychosis: The PACE 400 Study. JAMA Psychiatry. 2013 Aug 1;70(8):793-802.

31.Simon AE, Velthorst E, Nieman DH, Linszen D, Umbricht D, de Haan L. Ultra high-risk state for psychosis and non-transition: a systematic review. Schizophr Res. 2011;132(1):8-17.

32.Wiltink S, Velthorst E, Nelson B, McGorry PM, Yung AR. Declining transition rates to psychosis: the contribution of potential changes in referral pathways to an ultra–high-risk service. Early Interv Psychiatry. 2015;9(3):200-6.

33.Yung AR, Yuen HP, Berger G, Francey S, Hung T-C, Nelson B, et al. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophr Bull. 2007;33(3):673-81.

34.Fusar-Poli P. The hype cycle of the clinical high risk state for psychosis: the need of a refined approach. Schizophr Bull. 2018 Feb 15;44(2):250-3.

35.Fusar-Poli P, Schultze-Lutter F, Cappucciati M, Rutigliano G, Bonoldi I, Stahl D, et al. The dark side of the moon: meta-analytical impact of recruitment strategies on risk enrichment in the clinical high risk state for psychosis. Schizophr Bull. 2016;42(3):732-43.

36.van Os J, Guloksuz S. A critique of the “ultra-high risk” and “transition” paradigm. World Psychiatry. 2017;16(2):200-6.

37.McGorry PD, Nelson B, Markulev C, Yuen HP, Schäfer MR, Mossaheb N, et al. Effect of ω-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial. JAMA Psychiatry. 2017;74(1):19-27.

38.Nelson B, Amminger GP, Yuen HP, Markulev C, Lavoie S, Schäfer MR, et al. NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders—medium-term follow-up and clinical course. NPJ Schizophr. 2018;4(1):1-8.

39.Fusar-Poli P, Yung AR, McGorry P, van Os J. Lessons learned from the psychosis high-risk state: Towards a general staging model of prodromal intervention. Psychol Med. 2014;44(1):17.

40.McGorry PD, Yung AR, Phillips LJ. The “close-in” or ultra high-risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder. Schizophr Bull. 2003;29(4):771-90.

41.Thompson E, Millman ZB, Okuzawa N, Mittal V, DeVylder J, Skadberg T, et al. Evidence-based early interventions for individuals at clinical high risk for psychosis: a review of treatment components. J Nerv Ment Dis. 2015;203(5):342-51.

42.Birchwood M, Connor C, Lester H, Patterson P, Freemantle N, Marshall M, et al. Reducing duration of untreated psychosis: care pathways to early intervention in psychosis services. Br J Psychiatry. 2013;203(1):58-64.

43.Boydell KM, Gladstone BM, Volpe T. Understanding help seeking delay in the prodrome to first episode psychosis: a secondary analysis of the perspectives of young people. Psychiatr Rehabil J. 2006;30(1):54.

44.Klosterkötter J, Ruhrmann S, Schultze-Lutter F, Salokangas RK, Linszen D, Birchwood M, et al. The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe. World Psychiatry. 2005;4(3):161.

45.Rietdijk J, Hogerzeil SJ, van Hemert AM, Cuijpers P, Linszen DH, van der Gaag M. Pathways to psychosis: help-seeking behavior in the prodromal phase. Schizophr Res. 2011;132(2-3):213-9.

46.Schultze-Lutter F, Michel C, Schmidt SJ, Schimmelmann BG, Maric NP, Salokangas RKR, et al. EPA guidance on the early detection of clinical high risk states of psychoses. Eur Psychiatry. 2015;30(3):405-16.

47.Singh SP, Grange T. Measuring pathways to care in first-episode psychosis: a systematic review. Schizophr Res. 2006;81(1):75-82.

48.Stowkowy J, Colijn MA, Addington J. Pathways to care for those at clinical high risk of developing psychosis. Early Interv Psychiatry. 2013;7(1):80-3.

49.Ajnakina O, David AS, Murray RM. ‘At risk mental state’ clinics for psychosis —an idea whose time has come - and gone! Psychol Med. 2019 Mar;49(4):529-34.

50.Oliver D, Radua J, Reichenberg A, Uher R, Fusar-Poli P. Psychosis polyrisk score (PPS) for the detection of individuals at-risk and the prediction of their outcomes. Front Psychiatry. 2019;10:174.

51.Cooper S, Kring AM, Ellman LM. Attenuated positive psychotic symptoms and the experience of anhedonia. Early Interv Psychiatry. 2018;12(6):1188-92.

52.Millman ZB, Pitts SC, Thompson E, Kline ER, Demro C, Weintraub MJ, et al. Perceived social stress and symptom severity among help-seeking adolescents with versus without clinical high-risk for psychosis. Schizophr Res. 2018;192:364-70.

53.Pelletier-Baldelli A, Strauss GP, Visser KH, Mittal VA. Initial development and preliminary psychometric properties of the Prodromal Inventory of Negative Symptoms (PINS). Schizophr Res. 2017;189:43-9.

54.Bylsma LM, Morris BH, Rottenberg J. A meta-analysis of emotional reactivity in major depressive disorder. Clin Psychol Rev. 2008;28(4):676-91.

55.Cohen AS, Minor KS. Emotional experience in patients with schizophrenia revisited: meta-analysis of laboratory studies. Schizophr Bull. 2008;36(1):143-50.

56.Strauss GP, Ruiz I, Visser KH, Crespo LP, Dickinson EK. Diminished Hedonic response in neuroleptic-free youth at ultra high-risk for psychosis. Schizophr Res Cogn. 2018;12:1-7.

57.McDonald M, Christoforidou E, Van Rijsbergen N, Gajwani R, Gross J, Gumley AI, et al. Using online screening in the general population to detect participants at clinical high-risk for psychosis. Schizophr Bull. 2019;45(3):600-9.

58.Haining K, Matrunola C, Mitchell L, Gajwani R, Gross J, Gumley AI, et al. Neuropsychological deficits in participants at clinical high risk for psychosis recruited from the community: relationships to functioning and clinical symptoms. Psychol Med. 2020 Jan;50(1):77-85.

59.Cornblatt BA. The New York High Risk Project to the Hillside Recognition and Prevention (RAP) Program. Am J Med Genet. 2002;114(8):956-66.

60.Cornblatt BA, Lencz T, Smith CW, Correll CU, Auther AM, Nakayama E. The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr Bull. 2003;29(4):633-51.

61.Light G, Greenwood TA, Swerdlow NR, Calkins ME, Freedman R, Green MF, et al. Comparison of the heritability of schizophrenia and endophenotypes in the COGS-1 family study. Schizophr Bull. 2014;40(6):1404-11.

62.Snitz BE, MacDonald AW III, Carter CS. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull. 2006;32(1):179-94.

63.Carpenter WT. Clinical high risk controversies and challenge for the experts. Schizophr Bull. 2018;44(2):223-5.

64.Kapur S, Phillips AG, Insel TR. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatry. 2012;17(12):1174-9.

65.McGorry PD, Hartmann JA, Spooner R, Nelson B. Beyond the “at risk mental state” concept: transitioning to transdiagnostic psychiatry. World Psychiatry. 2018;17(2):133-42.

66.Simeonova DI, Nguyen T, Walker EF. Psychosis risk screening in clinical high-risk adolescents: a longitudinal investigation using the Child Behavior Checklist. Schizophr Res. 2014;159(1):7-13.

67.Thompson E, Kline E, Ellman LM, Mittal V, Reeves GM, Schiffman J. Emotional and behavioral symptomatology reported by help-seeking youth at clinical high-risk for psychosis. Schizophr Res. 2015;162(1-3):79-85.

68.Woods SW, Powers III AR, Taylor JH, Davidson CA, Johannesen JK, Addington J, et al. Lack of diagnostic pluripotentiality in patients at clinical high risk for psychosis: specificity of comorbidity persistence and search for pluripotential subgroups. Schizophr Bull. 2018;44(2):254-63.

69.Ilonen T, Heinimaa M, Korkeila J, Svirskis T, Salokangas RK. Differentiating adolescents at clinical high risk for psychosis from psychotic and non-psychotic patients with the Rorschach. Psychiatry Res. 2010;179(2):151-6.

70.Lindgren M, Manninen M, Laajasalo T, Mustonen U, Kalska H, Suvisaari J, et al. The relationship between psychotic-like symptoms and neurocognitive performance in a general adolescent psychiatric sample. Schizophr Res. 2010;123(1):77-85.

71.Modinos G, Allen P, Frascarelli M, Tognin S, Valmaggia L, Xenaki L, et al. Are we really mapping psychosis risk? Neuroanatomical signature of affective disorders in subjects at ultra high risk. Psychol Med. 2014;44(16):3491-501.

72.Millman ZB, Gold JM, Mittal VA, Schiffman J. The critical need for help-seeking controls in clinical high-risk research. Clin Psychol Sci. 2019;7(6):1171-89.

73.Allen P, Luigjes J, Howes OD, Egerton A, Hirao K, Valli I, et al. Transition to Psychosis Associated With Prefrontal and Subcortical Dysfunction in Ultra High-Risk Individuals. Schizophr Bull. 2012 Nov 1;38(6):1268-76.

74.Howes OD, Fusar-Poli P, Bloomfield M, Selvaraj S, McGuire P. From the Prodrome to Chronic Schizophrenia: The Neurobiology Underlying Psychotic Symptoms and Cognitive Impairments. Curr Pharm Des. 2012 Feb 1;18(4):459-65.

75.Kamin LJ. Predictability, surprise, attention, and conditioning. In Campbell BA, Church RM, editors Punishment and aversive behavior. Norwalk (US): Appleton-Century-Crofts; 1969. p. 279-96.

76.Dickinson A. The 28th Bartlett Memorial Lecture Causal Learning: An Associative Analysis. Q J Exp Psychol Sect B. 2001 Feb 1;54(1b):3-25.

77.Corlett PR, Fletcher PC. The neurobiology of schizotypy: Fronto-striatal prediction error signal correlates with delusion-like beliefs in healthy people. Neuropsychologia. 2012 Dec 1;50(14):3612-20.

78.Peters E, Joseph S, Day S, Garety P. Measuring Delusional Ideation: The 21-Item Peters et al. Delusions Inventory (PDI). Schizophr Bull. 2004 Jan 1;30(4):1005-22.

79.Alderson-Day B, Lima CF, Evans S, Krishnan S, Shanmugalingam P, Fernyhough C, et al. Distinct processing of ambiguous speech in people with non-clinical auditory verbal hallucinations. Brain. 2017 Sep 1;140(9):2475-89.

80.Powers AR, Mathys C, Corlett PR. Pavlovian conditioning-induced hallucinations result from overweighting of perceptual priors. Science. 2017 Aug 11;357(6351):596-600.

81.Powers AR, Kelley M, Corlett PR. Hallucinations as Top-Down Effects on Perception. Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 Sep 1;1(5):393-400.

82.Phillips WA, Silverstein SM. Convergence of biological and psychological perspectives on cognitive coordination in schizophrenia. Behav Brain Sci. 2003 Feb;26(1):65-82.

83.Silverstein SM. Visual Perception Disturbances in Schizophrenia: A Unified Model. In: Li M, Spaulding WD, editors. The Neuropsychopathology of Schizophrenia: Molecules, Brain Systems, Motivation, and Cognition. Cham (Switzerland): Springer International Publishing; 2016. p. 77-132.

84.Uhlhaas PJ, Silverstein SM. Perceptual Organization in Schizophrenia Spectrum Disorders: Empirical Research and Theoretical Implications. Psychol Bull. 2005;131(4):618-32.

85.Silverstein SM, Keane BP. Perceptual Organization Impairment in Schizophrenia and Associated Brain Mechanisms: Review of Research from 2005 to 2010. Schizophr Bull. 2011 Jul 1;37(4):690-9.

86.Silverstein SM, Keane BP, Wang Y, Mikkilineni D, Paterno D, Papathomas TV, et al. Effects of short-term inpatient treatment on sensitivity to a size contrast illusion in first-episode psychosis and multiple-episode schizophrenia. Front Psychol. 2013;4:466.

87.Horton HK, Silverstein SM. Visual Context Processing Deficits in Schizophrenia: Effects of Deafness and Disorganization. Schizophr Bull. 2011 Jul 1;37(4):716-26.

88.Silverstein SM, Elliott CM, Feusner JD, Keane BP, Mikkilineni D, Hansen N, et al. Comparison of visual perceptual organization in schizophrenia and body dysmorphic disorder. Psychiatry Res. 2015 Sep 30;229(1):426-33.

89.Uhlhaas PJ, Phillips WA, Mitchell G, Silverstein SM. Perceptual grouping in disorganized schizophrenia. Psychiatry Res. 2006 Dec 7;145(2):105-17.

90.Uhlhaas PJ, Phillips WA, Schenkel LS, Silverstein SM. Theory of mind and perceptual context-processing in schizophrenia. Cognit Neuropsychiatry. 2006 Jul 1;11(4):416-36.

91.Mittal VA, Gupta T, Keane BP, Silverstein SM. Visual context processing dysfunctions in youth at high risk for psychosis: Resistance to the Ebbinghaus illusion and its symptom and social and role functioning correlates. J Abnorm Psychol. 2015;124(4):953-60.

92.Uhlhaas PJ, Phillips WA, Silverstein SM. The course and clinical correlates of dysfunctions in visual perceptual organization in schizophrenia during the remission of psychotic symptoms. Schizophr Res. 2005 Jun 15;75(2):183-92.

93.Gruetzner C, Wibral M, Sun L, Rivolta D, Singer W, Maurer K, et al. Deficits in high- (>60 Hz) gamma-band oscillations during visual processing in schizophrenia. Front Hum Neurosci. 2013;7:88.

94.Rivolta D, Castellanos NP, Stawowsky C, Helbling S, Wibral M, Grützner C, et al. Source-Reconstruction of Event-Related Fields Reveals Hyperfunction and Hypofunction of Cortical Circuits in Antipsychotic-Naive, First-Episode Schizophrenia Patients during Mooney Face Processing. J Neurosci. 2014 Apr 23;34(17):5909-17.

95.Silverstein SM, Thompson JL, Gold JM, Schiffman J, Waltz JA, Williams TF, et al. Increased face detection responses on the mooney faces test in people at clinical high risk for psychosis. NPJ Schizophr. 2021 May 17;7(1):1-7.

96.Strauss GP, Waltz JA, Gold JM. A Review of Reward Processing and Motivational Impairment in Schizophrenia. Schizophr Bull. 2014 Mar 1;40(Suppl_2):S107-16.

97.Gold JM, Waltz JA, Matveeva TM, Kasanova Z, Strauss GP, Herbener ES, et al. Negative Symptoms and the Failure to Represent the Expected Reward Value of Actions: Behavioral and Computational Modeling Evidence. Arch Gen Psychiatry. 2012 Feb 1;69(2):129-38.

98.Treadway MT, Buckholtz JW, Schwartzman AN, Lambert WE, Zald DH. Worth the ‘EEfRT’? The effort expenditure for rewards task as an objective measure of motivation and anhedonia. PLoS One. 2009;4(8):e6598.

99.Culbreth AJ, Moran EK, Barch DM. Effort-based decision-making in schizophrenia. Curr Opin Behav Sci. 2018;22:1-6.

100.Gold JM, Strauss GP, Waltz JA, Robinson BM, Brown JK, Frank MJ. Negative symptoms of schizophrenia are associated with abnormal effort-cost computations. Biol Psychiatry. 2013;74(2):130-6.

101.Strauss GP, Whearty KM, Morra LF, Sullivan SK, Ossenfort KL, Frost KH. Avolition in schizophrenia is associated with reduced willingness to expend effort for reward on a Progressive Ratio task. Schizophr Res. 2016;170(1):198-204.

102.Strauss GP, Bartolomeo LA, Luther L. Reduced willingness to expend effort for rewards is associated with risk for conversion and negative symptom severity in youth at clinical high-risk for psychosis. Psychol Med. 2021 Jun 14;1-8.

103.Kirby KN, Petry NM, Bickel WK. Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. J Exp Psychol Gen. 1999;128(1):78.

104.Heerey EA, Robinson BM, McMahon RP, Gold JM. Delay discounting in schizophrenia. Cognit Neuropsychiatry. 2007;12(3):213-21.

105.Horan WP, Johnson MW, Green MF. Altered experiential, but not hypothetical, delay discounting in schizophrenia. J Abnorm Psychol. 2017;126(3):301.

106.Coleman AR, Moberg PJ, Ragland JD, Gur RC. Comparison of the Halstead-Reitan and infrared light beam finger tappers. Assessment. 1997;4(3):277-86.

107.Moore TM, Reise SP, Gur RE, Hakonarson H, Gur RC. Psychometric properties of the Penn Computerized Neurocognitive Battery. Neuropsychology. 2015;29(2):235-46.

108.Kring AM, Moran EK. Emotional response deficits in schizophrenia: insights from affective science. Schizophr Bull. 2008;34(5):819-34.

109.Lang PJ, Bradley MM, Cuthbert BN. International affective picture system (IAPS): Technical manual and affective ratings. NIMH Cent Study Emot Atten. 1997;1:39-58.

110.Gruber J, Strauss GP, Dombrecht L, Mittal VA. Neuroleptic-free youth at ultrahigh risk for psychosis evidence diminished emotion reactivity that is predicted by depression and anxiety. Schizophr Res. 2018;193:428-34.

111.Fusar-Poli P, Nelson B, Valmaggia L, Yung AR, McGuire PK. Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis. Schizophr Bull. 2014;40(1):120-31.

112.Rosen JL, Miller TJ, D’Andrea JT, McGlashan TH, Woods SW. Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. Schizophr Res. 2006;85(1-3):124-31.

113.Kristensen K, Cadenhead KS. Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res. 2007 May 30;151(1):151-4.

114.Sohn M, Moga DC, Blumenschein K, Talbert J. National trends in off-label use of atypical antipsychotics in children and adolescents in the United States. Medicine (Baltimore). 2016 Jun 10;95(23):e3784.

115.Walker EF, Cornblatt BA, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, et al. The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: A naturalistic study of the North American Prodrome Longitudinal Sample. Schizophr Res. 2009 Nov 1;115(1):50-7.

116.Woods SW, Walsh BC, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, et al. Current status specifiers for patients at clinical high risk for psychosis. Schizophr Res. 2014 Sep 1;158(1):69-75.

117.Addington J, Liu L, Buchy L, Cadenhead KS, Cannon TD, Cornblatt BA, et al. North American Prodrome Longitudinal Study (NAPLS 2): The Prodromal Symptoms. J Nerv Ment Dis. 2015 May;203(5):328-35.

118.Fusar-Poli P, Cappucciati M, Rutigliano G, Schultze-Lutter F, Bonoldi I, Borgwardt S, et al. At risk or not at risk? A meta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction. World Psychiatry. 2015;14(3):322-32.

119.Cornblatt BA, Auther AM, Niendam T, Smith CW, Zinberg J, Bearden CE, et al. Preliminary Findings for Two New Measures of Social and Role Functioning in the Prodromal Phase of Schizophrenia. Schizophr Bull. 2007 May 1;33(3):688-702.

120.Schlosser DA, Jacobson S, Chen Q, Sugar CA, Niendam TA, Li G, et al. Recovery From an At-Risk State: Clinical and Functional Outcomes of Putatively Prodromal Youth Who Do Not Develop Psychosis. Schizophr Bull. 2012 Nov 1;38(6):1225-33.

121.Cornblatt BA, Carrión RE, Auther A, McLaughlin D, Olsen RH, John M, et al. Psychosis Prevention: A Modified Clinical High Risk Perspective From the Recognition and Prevention (RAP) Program. Am J Psychiatry. 2015 Jun 5;172(10):986-94.

122.Pelletier-Baldelli A, Strauss GP, Visser KH, Mittal VA. Initial development and preliminary psychometric properties of the Prodromal Inventory of Negative Symptoms (PINS). Schizophr Res. 2017 Nov 1;189:43-9.

123.Strauss GP, Pelletier-Baldelli A, Visser KF, Walker EF, Mittal VA. A review of negative symptom assessment strategies in youth at clinical high-risk for psychosis. Schizophr Res. 2020 Aug;222:104-12.

124.Maxwell ME. Manual for the Family Interview for Genetic Studies (FIGS). Bethesda (US): Clinical Neurogenetics Branch, Intramural Research Program, National Insititute of Mental Health; 1992.

125.Janssen I, Krabbendam L, Bak M, Hanssen M, Vollebergh W, de Graaf R, et al. Childhood abuse as a risk factor for psychotic experiences. Acta Psychiatr Scand. 2004 Jan;109(1):38-45.

126.Dohrenwend BS, Askenasy AR, Krasnoff L, Dohrenwend BP. Exemplification of a Method for Scaling Life Events: The PERI Life Events Scale. J Health Soc Behav. 1978;19(2):205-29.

127.Wilkonson GS. The Wide Range Achievement Test administration manual. 3rd ed. Wilmington (US): Wide Range, Inc.; 1993.

128.Keefe RSE, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004 Jun 1;68(2):283-97.

129.Brandt J, Benedict RH. Hopkins verbal learning test-revised: professional manual. Lutz (US): Psychological Assessment Resources; 2001.

130.Loewy RL, Bearden CE, Johnson JK, Raine A, Cannon TD. The prodromal questionnaire (PQ): Preliminary validation of a self-report screening measure for prodromal and psychotic syndromes. Schizophr Res. 2005 Nov 1;79(1):117-25.

131.Llerena K, Park SG, McCarthy JM, Couture SM, Bennett ME, Blanchard JJ. The Motivation and Pleasure Scale-Self-Report (MAP-SR): Reliability and validity of a self-report measure of negative symptoms. Compr Psychiatry. 2013 Jul 1;54(5):568-74.

132.Cohen S, Kamarck T, Mermelstein R. A Global Measure of Perceived Stress. J Health Soc Behav. 1983;24(4):385-96.

133.Bernstein DP, Fink L, Handelsman L, Foote J, Lovejoy M, Wenzel K, et al. Initial reliability and validity of a new retrospective measure of child abuse and neglect. Am J Psychiatry. 1994;151(8):1132-6.

134.Bernstein DP, Ahluvalia T, Pogge D, Handelsman L. Validity of the Childhood Trauma Questionnaire in an Adolescent Psychiatric Population. J Am Acad Child Adolesc Psychiatry. 1997 Mar 1;36(3):340-8.

135.Schwartz D, Gorman AH. Community violence exposure and children’s academic functioning. J Educ Psychol. 2003;95(1):163-73.

136.Schwartz D, Proctor LJ. Community violence exposure and children’s social adjustment in the school peer group: the mediating roles of emotion regulation and social cognition. J Consult Clin Psychol. 2000 Aug;68(4):670-83.

137.Williams DR, Yu Y, Jackson JS, Anderson NB. Racial Differences in Physical and Mental Health: Socio-economic Status, Stress and Discrimination. J Health Psychol. 1997 Jul 1;2(3):335-51.

138.Taylor TR, Kamarck TW, Shiffman S. Validation of the Detroit area study discrimination scale in a community sample of older African American adults: The Pittsburgh healthy heart project. Int J Behav Med. 2004 Jun 1;11(2):88-94.

139.Krieger N, Smith K, Naishadham D, Hartman C, Barbeau EM. Experiences of discrimination: Validity and reliability of a self-report measure for population health research on racism and health. Soc Sci Med. 2005 Oct 1;61(7):1576-96.

140.Roberts RE, Phinney JS, Masse LC, Chen YR, Roberts CR, Romero A. The Structure of Ethnic Identity of Young Adolescents from Diverse Ethnocultural Groups. J Early Adolesc. 1999 Aug 1;19(3):301-22.

141.Ryder AG, Alden LE, Paulhus DL. Is acculturation unidimensional or bidimensio

引用本文

Vijay A. Mittal*,Lauren M. Ellman,Gregory P. Strauss,Elaine F. Walker,Philip R. Corlett,Jason Schiffman,Scott W. Woods,Albert R. Powers,Steven M. Silverstein,James A. Waltz,Richard Zinbarg,Shuo Chen,Trevor Williams,Joshua Kenney,James M. Gold. Computerized Assessment of Psychosis Risk, Journal of Psychiatry and Brain Science. 2021; 6; (3). https://doi.org/10.20900/jpbs.20210011.

文献评论

相关学者

相关机构